In this population, we estimated the fraction of time the patients had a VL above 1000 copies/mL although the previous VL had been undetectable. The study was a prospective nationwide cohort study. Denmark had a population of 5.5 million as of 31 December 2007, with an estimated HIV prevalence of approximately 0.07% in the adult population [6,7]. Patients with HIV infection are treated in one of the country’s eight specialized
medical centres, where they are seen on an out-patient basis at intended intervals of selleck screening library 12 weeks. Antiretroviral treatment is provided free of charge to all HIV-infected residents of Denmark. The national criteria for initiating HAART have previously been described . The Danish HIV Cohort study (DHCS), described in detail elsewhere, is
a population-based prospective nationwide cohort study of all HIV-infected individuals 16 years or older at diagnosis and who have been treated at Danish HIV centres after 1 January 1995 . Patients are consecutively enrolled, and multiple registrations are avoided through the use of a unique 10-digit civil registration number assigned to all individuals in Denmark at birth or upon immigration. Data are updated yearly and include demographics, date of HIV infection, AIDS-defining events, date and cause of death and antiretroviral treatment. CD4 cell counts and HIV RNA measurements were extracted electronically from laboratory data files. All VL analyses used in the study period were designed to measure VL<50 copies/mL. The cohort database also includes data on partnership and sexual behaviour Navitoclax order for some of the patients. As of 31 December 2007, the cohort included 4792 Danish residents. From the DHCS we included all HIV-1-positive patients who were on HAART, had a minimum of two VL tests and had at least one episode with VL <51 copies/mL for more than six consecutive months between 1 January 2000 and 1 January 2008.
The study model was based on the following oxyclozanide assumptions. 1 Patients with a VL≤1000 copies/mL are at low (negligible) risk of sexually transmitting HIV. We calculated the observation time from 6 months after the first VL<51 copies/mL to the date of: (1) the latest VL test <51 copies/mL before 1 January 2008; (2) the first VL>50 copies/mL; (3) the last VL test before antiretroviral treatment was stopped; (4) if there was an interval of more than 7 months between VL tests, the last VL test before this interval. Hence, patients with a VL test >50 and ≤1000 copies/mL were censored without contributing time at risk of transmitting HIV. Time at risk of transmitting HIV was calculated as 50% of the time from a previous VL<51 copies/mL to a following VL>1000 copies/mL. The outcome was the time at risk of transmitting HIV divided by the observation time. Poisson’s crude 95% confidence intervals (CIs) were calculated.